Quizartinib (Standard)

Quizartinib (Standard) is the analytical standard of Quizartinib. This product is intended for research and analytical applications. Quizartinib (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib induces apoptosis[1].

Product Specifications

CAS Number

[950769-58-1]

Product Name Alternative

AC220 (Standard) ; AC708 (Standard)

UNSPSC

12352005

Target

Apoptosis; Autophagy; FLT3; Ligands for Target Protein for PROTAC; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; Others; PROTAC; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/quizartinib-standard.html

Smiles

O=C(NC1=NOC(C(C)(C)C)=C1)NC2=CC=C(C=C2)C3=CN4C(SC5=CC(OCCN6CCOCC6)=CC=C45)=N3

Molecular Formula

C29H32N6O4S

Molecular Weight

560.67

References & Citations

[1]Zarrinkar PP, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) . Blood, 2009, 114 (14), 2984-2992.|[2]Puissant A, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10;25 (2) :226-42.|[3]Sun X, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019 Dec 24;4:64.